NCT05069935 2023-09-21
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
Fate Therapeutics
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
The Christie NHS Foundation Trust